These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1509 related items for PubMed ID: 14535531

  • 1. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW, Henderson IC.
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [Abstract] [Full Text] [Related]

  • 2. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
    Buzdar AU.
    Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
    [Abstract] [Full Text] [Related]

  • 3. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
    Buzdar AU, ATAC trialists' group.
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
    [Abstract] [Full Text] [Related]

  • 4. Future directions in the endocrine therapy of breast cancer.
    Hortobagyi GN.
    Breast Cancer Res Treat; 2003 Sep; 80 Suppl 1():S37-9. PubMed ID: 14535533
    [Abstract] [Full Text] [Related]

  • 5. Challenges in the endocrine management of breast cancer.
    Mouridsen HT, Rose C, Brodie AH, Smith IE.
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [Abstract] [Full Text] [Related]

  • 6. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
    Tobias JS.
    Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578
    [Abstract] [Full Text] [Related]

  • 7. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS, Forbes JF.
    Breast Cancer Res Treat; 2003 Dec; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [Abstract] [Full Text] [Related]

  • 8. Sequencing of endocrine therapies in breast cancer--integration of recent data.
    Carlson RW.
    Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S27-32; discussion S33-5. PubMed ID: 12353821
    [Abstract] [Full Text] [Related]

  • 9. The best use of adjuvant endocrine treatments.
    Pritchard KI.
    Breast; 2003 Dec; 12(6):497-508. PubMed ID: 14659127
    [Abstract] [Full Text] [Related]

  • 10. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B, Hess D, Köberle D, Senn I, Ballabeni P, Pagani O, Perey L, Aebi S, Rochlitz C, Goldhirsch A.
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [Abstract] [Full Text] [Related]

  • 11. Focus on anastrozole and breast cancer.
    Mokbel K.
    Curr Med Res Opin; 2003 Jun; 19(8):683-8. PubMed ID: 14687437
    [Abstract] [Full Text] [Related]

  • 12. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 13. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M.
    Clin Ther; 2007 Aug 01; 29(8):1535-47. PubMed ID: 17919537
    [Abstract] [Full Text] [Related]

  • 14. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A.
    Clin Breast Cancer; 2003 Apr 01; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [Abstract] [Full Text] [Related]

  • 15. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [Abstract] [Full Text] [Related]

  • 16. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group.
    Lancet; 2004 Jan 01; 365(9453):60-2. PubMed ID: 15639680
    [Abstract] [Full Text] [Related]

  • 17. Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
    Nabholtz JM.
    Am J Hosp Palliat Care; 2004 Jan 01; 21(6):457-65. PubMed ID: 15612238
    [Abstract] [Full Text] [Related]

  • 18. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N.
    Cancer Invest; 2005 Jan 01; 23(2):173-81. PubMed ID: 15813510
    [Abstract] [Full Text] [Related]

  • 19. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE.
    Cancer; 2004 Sep 15; 101(6):1311-22. PubMed ID: 15368322
    [Abstract] [Full Text] [Related]

  • 20. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K, Curran MP, Plosker GL.
    Drugs; 2004 Sep 15; 64(6):633-48. PubMed ID: 15018596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 76.